Literature DB >> 27194073

Clinical Trials in Neurovirology: Successes, Challenges, and Pitfalls.

Dietrich Haubenberger1, David B Clifford2.   

Abstract

Clinical trials in neurovirology illustrate the special challenges confronting investigators planning to study these conditions, as well as the contributions of successful trials in establishing appropriate management for these devastating diseases. This article reviews key examples of progress in neurovirology that have been spurred by clinical trials, emphasizing human herpes virus encephalitis, HIV, and JC virus. Clinical trials in the setting of neurovirological diseases are characterized by specific challenges, which may include small sample sizes, clinical presentations from life-threatening conditions to chronic courses of disease, regional and temporally restricted outbreaks scenarios, and the unavailability of validated diagnostic tests that can be rapidly deployed at the bedside. This review aims to highlight these methodological challenges and pitfalls in designing and executing clinical neurovirology trials, as well as to outline innovative trial designs, which could be useful in addressing common challenges.

Entities:  

Keywords:  Clinical trials; ethics; methodology; randomization; statistics

Mesh:

Year:  2016        PMID: 27194073      PMCID: PMC4965408          DOI: 10.1007/s13311-016-0440-8

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  79 in total

1.  Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.

Authors:  Gert Van Assche; Marc Van Ranst; Raf Sciot; Bénédicte Dubois; Séverine Vermeire; Maja Noman; Jannick Verbeeck; Karel Geboes; Wim Robberecht; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

2.  Longitudinally preserved psychomotor performance in long-term asymptomatic HIV-infected individuals.

Authors:  M A Cole; J B Margolick; C Cox; X Li; O A Selnes; E M Martin; J T Becker; H A Aronow; B Cohen; N Sacktor; E N Miller
Journal:  Neurology       Date:  2007-10-03       Impact factor: 9.910

3.  Non-randomized controls in cancer clinical trials.

Authors:  E A Gehan; E J Freireich
Journal:  N Engl J Med       Date:  1974-01-24       Impact factor: 91.245

4.  HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir.

Authors:  E R Lanier; G Sturge; D McClernon; S Brown; M Halman; N Sacktor; J McArthur; J H Atkinson; D Clifford; R W Price; D Simpson; G Torres; J Catalan; K Marder; C Power; C Hall; C Romero; B Brew
Journal:  AIDS       Date:  2001-04-13       Impact factor: 4.177

5.  Diseases that mimic herpes simplex encephalitis. Diagnosis, presentation, and outcome. NIAD Collaborative Antiviral Study Group.

Authors:  R J Whitley; C G Cobbs; C A Alford; S J Soong; M S Hirsch; J D Connor; L Corey; D F Hanley; M Levin; D A Powell
Journal:  JAMA       Date:  1989-07-14       Impact factor: 56.272

6.  A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders.

Authors: 
Journal:  Neurology       Date:  1998-03       Impact factor: 9.910

7.  Long-Term Mortality in HIV-Infected Individuals 50 Years or Older: A Nationwide, Population-Based Cohort Study.

Authors:  Rebecca A Legarth; Magnus G Ahlström; Gitte Kronborg; Carsten S Larsen; Court Pedersen; Gitte Pedersen; Rajesh Mohey; Jan Gerstoft; Niels Obel
Journal:  J Acquir Immune Defic Syndr       Date:  2016-02-01       Impact factor: 3.731

8.  Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Authors:  Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis
Journal:  Arch Neurol       Date:  2008-01

9.  Identification and characterization of mefloquine efficacy against JC virus in vitro.

Authors:  Margot Brickelmaier; Alexey Lugovskoy; Ramya Kartikeyan; Marta M Reviriego-Mendoza; Norm Allaire; Kenneth Simon; Richard J Frisque; Leonid Gorelik
Journal:  Antimicrob Agents Chemother       Date:  2009-03-02       Impact factor: 5.191

10.  Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder.

Authors:  Thomas M Gates; Lucette A Cysique; Krista J Siefried; Joga Chaganti; Kirsten J Moffat; Bruce J Brew
Journal:  AIDS       Date:  2016-02-20       Impact factor: 4.177

View more
  1 in total

Review 1.  Insights into the pathogenesis of herpes simplex encephalitis from mouse models.

Authors:  Mathieu Mancini; Silvia M Vidal
Journal:  Mamm Genome       Date:  2018-08-23       Impact factor: 2.957

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.